Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Key finding

In HIV patients with abdominal fat, tesamorelin over 6 months reduced visceral fat and produced modest reductions in liver fat (NAFLD), linking GHRH-analog therapy to ectopic-fat improvement.

Method / model

Randomised, double-blind, placebo-controlled trial (n=54 randomised).

Relevance

Supports tesamorelin / GH-axis effects on visceral + hepatic fat.

Stanley, T.L., et al. (2014). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV, 1(3), e120-e127.